# Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632

> **NCT02779140** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Botulism

## Interventions

- **BIOLOGICAL:** NTM-1632
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02779140
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-01
- **Primary completion:** 2017-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779140, "Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02779140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*